Search research articles
Contact Us
Filters
Showing results (181-190 of 218) with videos related to
Page
of 22
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
June 8, 2021
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases
Anne Zaremba, Manuel Philip, Jessica C Hassel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2024
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma
Eleanor E Handel, Janet McKeown, Joe Wei, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 26, 2024
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy
Amelia M Taylor, Janet McKeown, Florentia Dimitriou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 21, 2023
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma
Adriana Hepner, Judith M Versluis, Roslyn Wallace, et al.
Nature Cancer
|
August 14, 2023
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Renáta Váraljai, Lisa Zimmer, Yahya Al-Matary, et al.
Nature Cancer
|
July 31, 2023
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Renáta Váraljai, Lisa Zimmer, Yahya Al-Matary, et al.
The Lancet. Oncology
|
May 14, 2021
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
Ines Pires da Silva, Tasnia Ahmed, Irene L M Reijers, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 30, 2024
Early versus late response to PD-1-based immunotherapy in metastatic melanoma
Georg C Lodde, Fang Zhao, Rudolf Herbst, et al.
British Journal of Cancer
|
October 22, 2020
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
Prachi Bhave, Lalit Pallan, Georgina V Long, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 11, 2021
Hematological immune related adverse events after treatment with immune checkpoint inhibitors
Rafaela Kramer, Anne Zaremba, Alvaro Moreira, et al.
Page
of 22
Search research articles
Search
Showing results (181-190 of 218) with videos related to
Sort By:
Page
of 22
European Journal of Cancer (Oxford, England : 1990)
|
June 8, 2021
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases
Anne Zaremba, Manuel Philip, Jessica C Hassel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2024
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma
Eleanor E Handel, Janet McKeown, Joe Wei, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 26, 2024
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy
Amelia M Taylor, Janet McKeown, Florentia Dimitriou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 21, 2023
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma
Adriana Hepner, Judith M Versluis, Roslyn Wallace, et al.
Nature Cancer
|
August 14, 2023
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Renáta Váraljai, Lisa Zimmer, Yahya Al-Matary, et al.
Nature Cancer
|
July 31, 2023
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Renáta Váraljai, Lisa Zimmer, Yahya Al-Matary, et al.
The Lancet. Oncology
|
May 14, 2021
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
Ines Pires da Silva, Tasnia Ahmed, Irene L M Reijers, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 30, 2024
Early versus late response to PD-1-based immunotherapy in metastatic melanoma
Georg C Lodde, Fang Zhao, Rudolf Herbst, et al.
British Journal of Cancer
|
October 22, 2020
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
Prachi Bhave, Lalit Pallan, Georgina V Long, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 11, 2021
Hematological immune related adverse events after treatment with immune checkpoint inhibitors
Rafaela Kramer, Anne Zaremba, Alvaro Moreira, et al.
Page
of 22